NASDAQ: CHRSCoherus Biosciences Inc Stock
$1.12+0.11 (+10.89%)
Updated Apr 17, 2025
CHRS Price
$1.12
Fair Value Price
N/A
Market Cap
$129.80M
52 Week Low
$0.66
52 Week High
$2.43
P/E
4.48x
P/B
-0.98x
P/S
0.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$266.96M
Earnings
$28.51M
Gross Margin
56%
Operating Margin
20.85%
Profit Margin
10.7%
Debt to Equity
-4.4
Operating Cash Flow
-$20M
Beta
1.46
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CHRS Overview
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CHRS's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CHRS
Ranked#425 of 463
Ranked#425 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CHRS news, forecast changes, insider trades & much more!
CHRS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CHRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHRS was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHRS is good value based on its earnings relative to its share price (4.48x), compared to the US market average (27.98x)
P/E vs Market Valuation
CHRS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more CHRS due diligence checks available for Premium users.
Valuation
CHRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.48x
Industry
-177.72x
Market
27.98x
CHRS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CHRS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CHRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.98x
Industry
4.05x
CHRS's financial health
Profit margin
Revenue
$54.1M
Net Income
-$50.7M
Profit Margin
-93.6%
CHRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CHRS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$448.5M
Liabilities
$580.5M
Debt to equity
-4.4
CHRS's short-term assets ($341.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRS's short-term assets ($341.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CHRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$28.6M
Investing
-$542.0k
Financing
$231.0k
CHRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHRS vs Biotech Stocks
Coherus Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.